Clinicopathological characteristics and prognosis of breast cancer patients with type 2 diabetes mellitus

Abstract

Abstract. Type 2 diabetes mellitus (T2DM) can increase the risk of several common cancers, including breast cancer (BC). The purpose of the present study was to investigate the clinicopathological features and prognosis of BC patients with or without T2DM. Seventy-eight patients were diagnosed with T2DM prior to the diagnosis of BC in the Cancer Hospital of Shantou University Medical College (Shantou, China) between 2002 and 2008. A total of 300 BC patients without T2DM were randomly selected as study controls during the same period. The clinicopathological characteristics, overall survival (OS) and disease-free survival (DFS) rates of these two groups were compared. Fifty-five BC patients and 133 control patients with T2DM were >50 years old (70.5 and 44.3%, respectively). There were more T2DM BC patients with body mass index (BMI) ≥25 kg/m 2 (46.2 vs. 23.3%) and these patients had a higher rate of lymph node involvement (67.9 vs. 55.0%). The DFS of the two groups was 32.1 vs. 22.3%. The OS of the two groups was 24.4 vs. 13.7%. Following adjustment for BMI, tumor-node metastasis stage and stratification of age, the relapse risk of T2DM BC patients was >2-fold higher than that of the control group in the estrogen receptor/progesterone receptor (ER/PR)-positive patients. In Her-2-negative BC patients, the relapse risk of T2DM patients was 2.237-fold higher than that of the non-T2DM patients. In conclusion, T2DM BC patients were significantly older and more likely to be overweight, and had more lymph nodes involvement. T2DM was associated with poor prognosis in ER/PR positive or Her-2-negative BC patients.

Type 2 Diabetes, but Not Insulin (Analog) Treatment, Is Associated With More Advanced Stages of Breast Cancer: A National Linkage of Cancer and Pharmacy Registries

“…The literature regarding the association between diabetes and pathologic breast cancer characteristics is scarce (6,22-27), but the majority is consistent with our findings. These studies also concluded that patients with T2D presented with larger tumors (23,24,26,27), higher rates of lymph node metastasis (22)(23)(24), more advanced stages (22,27), and higher-grade tumors (25). Furthermore, these studies (6,(22)(23)(24)(25)(26)(27) also determined the association between diabetes and hormone receptor status (ER, PR, and HER2).…”

Diabetes mellitus and prognosis in women with breast cancer

“…All of the included articles were published from 2001 to 2016. Of the 17 articles, 3 studies [26,28,32] had a prospective cohort design, 10 studies [17–23,27,29,30] had a retrospective cohort design, and 4 studies [24,25,31,33] had a case–control design. The total number of breast cancer patients was 48,315, with study populations ranging from 378 to 6342 in the individual articles.…”

Correlations of microRNA-124a and microRNA-30d with clinicopathological features of breast cancer patients with type 2 diabetes mellitus

“…The relative risk for mortality of BC patients has been reported to be twofold greater in BC patients with DM than in those without DM (Liao et al 2011), and the epidemiologic evidences showed that DM patients have a significant higher risk of BC and is closely associated with a poor prognosis of BC patients (Luo et al 2014; Oppong et al 2014). The BC patients with T2DM had been reported to be more likely to associate with a higher incidence of lymph nodes and were at an advanced tumor stage, indicating a shorter survival time (He et al 2015). …”